Article

Non-randomised phase II trial of hyperbaric oxygen therapy in patients with chronic arm lymphoedema and tissue fibrosis after radiotherapy for early breast cancer.

Department of Radiotherapy, Royal Marsden NHS Trust, Sutton, Surrey SM2 5PT, UK.
Radiotherapy and Oncology (Impact Factor: 4.52). 03/2004; 70(3):217-24. DOI: 10.1016/S0167-8140(03)00235-4
Source: PubMed

ABSTRACT Radiation-induced arm lymphoedema is a common and distressing complication of curative treatment for early breast cancer. Hyperbaric oxygen (HBO(2)) therapy promotes healing in bone rendered ischaemic by radiotherapy, and may help some soft-tissue injuries too, but is untested in arm lymphoedema.
Twenty-one eligible research volunteers with a minimum 30% increase in arm volume in the years after axillary/supraclavicular radiotherapy (axillary surgery in 18/21 cases) were treated with HBO(2). The volunteers breathed 100% oxygen at 2.4 ATA for 100 min in a multiplace hyperbaric chamber on 30 occasions over a period of 6 weeks. The volume of the ipsilateral limb, measured opto-electronically by a perometer and expressed as a percentage of contralateral limb volume, was selected as the primary endpoint. A secondary endpoint was local lymph drainage expressed as fractional removal rate of radioisotopic tracer, measured using lymphoscintigraphy.
Three out of 19 evaluable patients experienced >20% reduction in arm volume at 12 months. Six out of 13 evaluable patients experienced a >25% improvement in (99)Tc-nanocolloid clearance rate from the ipsilateral forearm measured by quantitative lymphoscintigraphy at 12 months. Overall, there was a statistically significant, but clinically modest, reduction in ipsilateral arm volume at 12 months follow-up compared with baseline (P = 0.005). The mean percentage reduction in arm volume from baseline at 12 months was 7.51. Moderate or marked lessening of induration in the irradiated breast, pectoral fold and/or supraclavicular fossa was recorded clinically in 8/15 evaluable patients. Twelve out of 19 evaluable patients volunteered that their arms felt softer, and six reported improvements in shoulder mobility at 12 months. No significant improvements were noted in patient self-assessments of quality of life.
Interpretation is limited by the absence of a control group. However, measurement of limb volume by perometry is reportedly reliable, and lymphoscintigraphy is assumed to be operator-independent. Taking all data into account, there is sufficient evidence to justify a double-blind randomised controlled trial of hyperbaric oxygen in this group of patients.

0 Bookmarks
 · 
68 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: This article outlines the therapeutic mechanisms of hyperbaric oxygenation in acute stroke, based on information obtained from peer-reviewed medical literature. Hyperbaric oxygen is an approved treatment modality for ischemia-reperfusion injury in several conditions. It maintains the viability of the marginal tissue, reduces the mitochondrial dysfunction, metabolic penumbra, and blocks inflammatory cascades observed in acute stroke. Basic and clinical data suggest that hyperbaric oxygen could be a safe and effective treatment option in the management of acute stroke. Further work is needed to clarify its clinical utility when applied within the treatment window of "gold standard" treatments (<3-5 hours).
    Critical care nursing quarterly 36(3):290-8.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The hypothesis being tested in this project is that a greater proportion of patients who develop radiation-induced subcutaneous late tissue morbidity possess a variant allele in the ATM gene compared with patients who do not suffer these complications. An additional objective is to determine the functional impact upon the protein encoded by the ATM gene for each genetic alteration identified and subsequent cellular radiosensitivity. The specific aims of this project are to (1) screen 50 breast cancer patients for ATM genetic alterations who developed radiation induced late subcutaneous tissue morbidity (2) establish a control group and screen 100 patients without evidence of this late radiation reaction and (3) perform functional studies using cells from patients identified as ATM carriers to determine to what extent each ATM variant identified affects radiosensitivity and normal activity of the protein produced by the ATM gene.
    06/2006;
  • [Show abstract] [Hide abstract]
    ABSTRACT: 1) Provide a critical analysis of the contemporary published research pertaining to complementary, alternative, and other non-Complete Decongestive Therapies (CDT) for treatment of lymphedema (LE); and 2) Provide practical applications of that evidence to improve care of patients with or at risk for LE. TYPE: This study meets the defining criteria as a systematic search and review since it includes varied study types. All studies that met the inclusion criteria were evaluated for weight of evidence and value. The systematic search and review includes manuscripts published in the contemporary literature (2004-2012). Publications published from 2004-2011 were retrieved from 11 major medical indices using search terms for LE and management approaches. Literature archives were examined through 2012. Data extraction included study design, objectives pertaining to LE, number and characteristics of participants, interventions, and outcomes. Study strengths and weaknesses were summarized. Study evidence was categorized according to the Oncology Nursing Society Putting Evidence into Practice (PEP) level-of-evidence guidelines after achieving consensus among the authors. No authors participated in development of nor benefitted from the review of these modality methods or devices. ology: Data extraction from 85 studies was reviewed in four sub-categories: Botanical, Pharmaceutical, Physical Agent Modality (PAM), and Modalities of Contemporary Value (MCV). After review, 47 articles were excluded, leaving 16 articles on botanicals and pharmaceuticals and 22 articles for PAM/MCV. Pharmaceuticals were later excluded. The authors concluded Botanicals had generated sufficient studies to support a second, more specific systematic review; thus, Botanicals are reported elsewhere. It was found that limited high-level evidence was available for all categories. Well-constructed randomized control trials (RCT) related specifically to LE were limited. Objective outcome measures over time were absent from several studies. Rationale for the use and benefits of the specific modality, as related to LE, was often anecdotal. Subject sizes were less than 50 for most studies. No interventions were ranked as "recommended for practice" based on the PEP guidelines. Two treatment modalities in three studies were ranked as "likely to be effective" in reducing LE, or in managing secondary LE complications. Consideration should be given that many of the PAM demonstrate long-standing support within the literature with broad parameters for therapeutic application and benefit for secondary conditions associated with LE. However, further investigation as to their individual, contributory value and the factors that contribute to their efficacy, specific to LE, have not been determined. It is also significant to mention that the majority of these studies focused on breast cancer-related lymphedema. Studies exploring treatment interventions for lymphedema-related vascular disorders (e.g., chronic venous insufficiency, congenital dysphasia, trauma) were sparse. Limitations of the literature support the recommendations for future research to further examine the level of evidence in these modalities for LE management.
    PM&R 09/2013; · 1.37 Impact Factor

Full-text (2 Sources)

Download
64 Downloads
Available from
May 17, 2014